K50-K52
Conditions
Interventions
Group 1: Within the routine blood sampling, blood is also taken from patients for EDTA whole blood and serum collection and these samples are transferd to the biobank. Patients will also receive fecal
Sponsors
LMU Klinikum
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients (m/f/d) who are treated as inpatients, day inpatients, day patients, outpatients or consultants by the Medical Clinic and Polyclinic II of the LMU Hospital. The focus is on the inclusion of patients with IBD and other inflammatory diseases of the gastrointestinal tract.
Exclusion criteria
Exclusion criteria: Lack of consent for biobank participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim is to establish a prospective biobank to investigate the progression of inflammatory gastrointestinal diseases and their precursors. These included basic research as well as applied research for the detection of diseases (diagnosis), the prediction of their course (prognosis) as well as their treatment (therapy) and prevention (prevention). The purpose of the biobank is thus limited to a group of diagnoses and risk cohorts, but not to a single question or disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| a) The recording, isolation and characterization of bacteria, archaebacteria, eukaryotes or viruses in the gastrointestinal tract (intestinal microbiome). b) Validation of liquid biopsy-based non-invasive tests for the early diagnosis and prediction of the course of diseases in at-risk patients. c) Identification and validation of new genetic risk variants, d) Evaluation of treatment strategies recommended in guidelines under "real-life" conditions. e) Comparison Biomaterials obtained from patients with samples from organoid cultures and mouse models with the aim of optimizing measurement methods and reducing animal experiments. | — |
Countries
Germany
Contacts
Public ContactBenjamin Misselwitz
LMU Klinikum
Outcome results
None listed